RxDoctor Payments Data

Lonika Majithia, MD

Radiation Oncology · Fairfax, VANPI 1376833624

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,150 of the $4,733 with a category attached, or 66.6%. AstraZeneca accounts for 69.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $3,356 and has fallen 95.1% since, to $165 in 2025.

$4,733in general payments, 2019–2025

Across 20 payments — averaging $236.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Boston Scientific$278
  • Medtec LLC$182
  • Novartis$162
  • Visionrt, Inc.$150
  • Novocure Inc.$141
  • plus $537 from 7 others

What the payments were for

  • Consulting fees$3,15067%
  • Food & beverage$1,58333%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$3,283
Boston Scientific2$278
Medtec LLC1$182
Novartis2$162
Visionrt, Inc.1$150
Novocure Inc.2$141
Elekta, Inc.1$139
Sirtex Medical Inc1$110
Angiodynamics, Inc.1$106
Teleflex LLC2$69
Siemens Medical Solutions USA, Inc.2$59
Brainlab, Inc.1$40
Fortovia Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,733 in reported general payments places this provider in the 85th percentile of 121 radiation oncology providers in Virginia.

See all radiation oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$391,427
Medicare patients
716
Services billed
4,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →